Kymera is developing a heterobifunctional small molecule drug platform to target previously undruggable proteins for degradation. Using a new therapeutic modality, Kymera’s therapeutics redirect the ubiquitin proteosome system for targeted protein degradation.
IPO in August 2020 (NASDAQ: KYMR).
